4D Pharma collaborates with Merk & Co for Live Biotherapeutics vaccines
Abraham Darwyne
Company News - 2 min read
07:57, 8th October 2019

4D Pharma (DDDD) FOLLOW on Tuesday announced a research collaboration with Merck & Co, to discover and develop Live Biotherapeutics for vaccines.

4D pharma’s proprietary MicroRx® platform will be paired with MSD's development and commercialisation expertise, to discover and develop vaccines in up to three indications, which were undisclosed.

The AIM listed pharmaceutical company also entered into an option to license agreement with MSD, where it is eligible for upfront cash payments for each indication and up to $347.5 million in option exercise and development and regulatory milestone payments.

It is also eligible for tiered royalties on annual net sales of any licensed products derived from the collaboration.

4D Pharma also has the right, subject to certain conditions, to cause MSD to purchase $5 million of 4D shares during the first year of the collaboration.

Shares in 4D Pharma were trading 25% higher at 130p in early morning trading

Duncan Peyton, 4D's Chief Executive Officer, commented: "This research collaboration agreement brings together 4D's innovation in the microbiome space and MSD's track record of developing cutting-edge vaccines.”

He added: “MSD and 4D have worked closely combining world leading science to develop a workplan to advance the understanding of this field, with the aim of generating a new class of vaccines in areas of high unmet need."

MSD will be responsible for development, manufacturing and commercialisation following the exercise of any of its exclusive options.

Daria Hazuda, Chief Scientific Officer of MSD's Exploratory Science Center and MSD's Vice President of Infectious Diseases and Vaccines Discovery Research, commented: "A key element of our focus in the Exploratory Science Center is the evaluation of emerging new areas of biology that have the potential to offer major beneficial impact to human health.”

“By applying 4D's MicroRx® technology we hope to gain meaningful insights into the role for the host microbiome in modulating the immune response and ultimately protection conferred by vaccines."

Follow News & Updates from 4D Pharma here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles